CANF – can-fite biopharma ltd american depositary shares, each representing two (2) ordinary shares (US:NASDAQ)

News

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson [Yahoo! Finance]
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
Can-Fite BioPharma (NYSE:CANF) had its price target lowered by analysts at D. Boral Capital from $11.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com